Monogenic and Syndromic Obesity

Sonali Malhotra, MD Pediatric Endocrinology/Obesity Medicine Diplomate, ABOM Harvard Medical School *Massachusetts General Hospital for Children*



Disclosures

Speaker Bureau: Rhythm Pharmaceuticals





Learning Objectives

- Review the energy balance regulation pathway.
- To introduce rare disorders of obesity, also known as monogenic obesity.
- Review clinical features of syndromic genetic disorders that cause obesity



Objectives

- To discuss the energy balance regulation
- To introduce rare disorders of obesity, also known as monogenic obesity.
- Review clinical features of syndromic genetic disorders that cause obesity







Objectives

- To discuss the energy balance regulation
- To introduce rare disorders of obesity, also known as monogenic obesity.
- Review clinical features of syndromic genetic disorders that cause obesity



Monogenic Obesity



Congenital Leptin Deficiency

- Cause: mutations in gene for leptin (LEP)
- Phenotype: Hyperphagia with severe, early onset obesity, altered immune function and delayed puberty
- Prevalence: EXTREMELY RARE only several case reports in consanguineous families*
- Diagnostic test: leptin level (undetectable), genetic testing
- Treatment: recombinant leptin



*Mostly found in consanguineous families. Adapted from Bell CG, et al. Nat Rev Genet. 2005;6(3):221-34.

Leptin deficiency Case

- Female patient with rapid early onset weight gain at 4 months of age
- Hyperphagia (demanding food continuously, ate much more than siblings)
- Developed growth abnormalities in leg bones
- -corrective leg surgery
- -liposuction of lower limb fat to try to improve mobility

Montague et al Nature. 1997;387:903-908



Leptin deficiency Case continued..

- Endocrine tests
 - Serum Leptin undetectable
 - Insulin (Elevated markedly)
 - Proinsulin (4 times the ULN)
- Genetic tests:
 - Homozygous LEP frameshift mutation detected
 - Parents were heterozygous
- Eligible for treatment with recombinant human leptin replacement

Montague et al Nature. 1997;387:903-908





weight = 40kg, age 3yrs BEFORE LEPTIN



weight = 29kg, age 6yrs AFTER LEPTIN Leptin treatment in Leptin deficiency







Source: Endocrinology Reviews

Monogenic Obesity:



Leptin receptor deficiency

- **Cause:** mutations in gene for leptin receptor (*LEPR*)
- Phenotype: Hyperphagia with severe, early-onset obesity and problems with sexual development [same as leptin deficiency]
- **Prevalence:** EXTREMELY RARE- only several case reports*
- **Diagnostic test:** leptin level [very high], genetic testing
- **Treatment:** none available, MC4R agonist in development



LEPR Deficiency Case 2

- 2-year-old female presents with progressive severe obesity from birth
- Consoled only by food
- Parents were unable to maintain nutritional plan owing to hyperphagia



Kleinendorst L, et al. *BMJ Case Rep.* 2017;2017:bcr-2017-221067. Image reproduced from Kleinendorst L, et al. *BMJ Case Rep* 2017;2017:bcr-2017-221067.

Case report: Leptin receptor deficiency

- No developmental delays or other abnormal clinical features present.
- Thyroid and cortisol levels normal
- Leptin levels elevated because of fat mass
- Sequenced MC4R and found no mutations
 - -Subsequently sequenced 52 obesity related genes.
- Found compound heterozygous LEPR mutations





Monogenic Obesity:



POMC mutations

(Pro-opiomelanocortin)

- Cause: mutation in POMC gene
- Phenotype: early-onset obesity, adrenal insufficiency, red hair
- Prevalence: <1/1,000,000
- **Diagnostic test:** distinct phenotype, low cortisol, genetic testing
- Treatment:
 - Hydrocortisone replacement for adrenal insufficiency

Krude, Gruters, Trends in Endocrinology & Metabolism, 2000.

POMC Deficiency: Case Report

- 2-year-old Hispanic boy presents with early onset severe obesity
 - -Neonatal Hypoglycemia
 - -Frequent respiratory infections
 - -Speech and motor delay
- Marked Hyperphagia
- Associated Adrenal Insufficiency and hypothyroidism
 - -Hydrocortisone and levothyroxine

replacement



Hilado and Randhawa.J Pediatric Endocrinol Metab.2018;31:815-819

POMC Deficiency: Case 3 (cont'd)

- Negative testing for Prader-Willi syndrome
- Identified homozygous *POMC* mutation in exon 3
- Patient was treated with metformin
- Over a 3-year metformin treatment span, BMI decreased from 34.9 kg/m² to 32.9 kg/m²



BMI = body mass index. Millington GW. Nutr Metab (Lond). 2007;4:18. Open Access.

POMC Deficiency: What next? MC4R agonists





Monogenic Obesity:





PC1/3 mutations (Pro-hormone convertase)

- Cause: mutation in PCSK1 gene
- **Phenotype:** severe obesity, low insulin, chronic diarrhea, problems with sexual development
- Prevalence: VERY rare- only several case reports*
- **Diagnostic test:** high pro-hormone levels, genetic testing
- Treatment:
 - o Hormone replacement

PCSK1 Deficiency Case Report

- 6-year-old male with severe early onset obesity
- Malabsorptive diarrhea noted at the age of 8 days
- During first year of life required specialized formulas for weight gain
- Reported to be hyperphagic with food seeking behavior at the age of 2.

Farooqi et al.JCEM 2007;92:3369-3373





PCSK1 Deficiency Case <u>4 (cont'd)</u>

Clinical features of severe early onset obesity, abnormal Insulin/proinsulin ratio and sequencing diagnosed with prohormone convertase (PC) 1/3 deficiency

• Elevated ACTH precursor

(549 pmol/l Ref range:78 pmol/l)

• Low free T₄



T₄ = thyroxine. Farooqi IS, et al. *J Clin Endocrinol Metab.* 2007;92(9):3369-73.

Monogenic Obesity:

MC4R mutations



Learning Objectives

- Review the energy balance regulation pathway.
- To introduce rare disorders of obesity, also known as monogenic obesity.
- Review clinical features of syndromic genetic disorders that cause obesity



Syndromic obesity

- The most frequent forms of syndromic obesity are Prader-Willi and Bardet-Biedl syndrome.
- Not a single gene mutation but multiple genes are effected-- and have more features besides just obesity
- Mechanism of obesity is less well understood





Prader-Willi Syndrome



Prader-Willi Syndrome





Prader-Willi Syndrome



Prader-Willi Syndrome





Clinical characteristics of Prader-Willi Syndrome

- Birth to 2 years : Hypotonia with poor suck
- 2–6 years
 Hypotonia with poor suck
 Global developmental delays
- 6–12 years : History of hypotonia with poor suck Global developmental delay Excessive eating (hyperphagia, obsession with food) Central obesity

Cassidy, S., & Driscoll, D. (2009). *EJHG*, 17(1), 3-13.



Figure 1 Hypotonia of infancy in a one-month-old male with PWS. Note frogleg position and need for a feeding tube. Also note dolichocephaly and hypoplastic, empty scrotum.

Clinical characteristics of Prader-Willi Syndrome

12 years through adulthood

Intellectual disability Hyperphagia with central obesity Hypothalamic hypogonadism Typical behavior problems (including temper tantrums and compulsive features)

Cassidy, S., & Driscoll, D. (2009). *EJHG*, 17(1), 3-13.





MassGeneral Hospital for Children[®]



Bardet-Biedl Syndrome (BBS)

- Mutation in BBS genes
- BBS genes are involved in trafficking LEPR to the neuronal cell surface
- Also genetic defect in cilia





Clinical Characteristics

- Diagnostic criteria : 4 primary features OR 3 primary plus 2 secondary features
- Primary Criteria:
 - -Rod cone dystrophy
 - -Polydactyly
 - -Obesity
 - -Genital anomalies
- Renal anomalies
- Learning diabilities



Secondary Criteria:

- Speech delay
- Developmental delay
- Diabetes mellitus
- Dental anomalies
- Congenital Heart disease
- Brachydactyly
- Ataxia/Poor coordination
- Anosmia/Hyposmia

Forsythe and Beales.Eur J Hum genet.2013;21:8-13

Alström syndrome: ALMS1 deficiency

- Mutation in ALMS1 gene.
- ALMS1 plays role in LEPR signaling and POMC neuron survival
- <1:1,000,000 (~900 cases)



Alström syndrome: Clinical Characteristics

Diagnostic criteria: 2 major criteria, or 1 major criterion plus any 2 minor criteria¹

 ALMS1 mutation in 1 allele and/or family history of Alström syndrome Vision (nystagmus, photophobia) ALMS1 mutation in 1 allele ind/or family history of Alström syndrome Vision (nystagmus, photophobia, decreased acuity, cone dystrophy [sometimes diagnosed as retinitis pigmentosa]² by ERG) ALMS1 mutation in 1 allele and/or family history of Alström syndrome Vision (nystagmus, photophobia, decreased acuity, cone dystrophy [sometimes diagnosed as retinitis pigmentosa]² by ERG) AlMS1 mutation in 1 allele and/or family history of Alström syndrome Vision (legal blindness, history of nystagmus in infancy/childhood, cone and rod dystrophy by ERG) Alström syndrome Vision (legal blindness, history of nystagmus in infancy/childhood, cone and rod dystrophy by ERG) 	Age, years	Major criteria	Minor criteria
 Alström syndrome Vision (nystagmus, photophobia, decreased acuity, cone dystrophy [sometimes diagnosed as retinitis pigmentosa]² by ERG) History of dilated cardiomyopathy with congestive heart failure Hearing loss Advanced bone age Hepatic dysfunction Renal failure Obesity and/or insulin resistance and/or T2DM History of dilated cardiomyopathy with congestive heart failure Hearing loss Hearing loss Hepatic dysfunction Renal failure Obesity and/or insulin resistance and/or T2DM History of dilated cardiomyopathy with congestive heart failure Hearing loss History of stagmus in infancy/childhood, cone and rod dystrophy by ERG) 	<2	Alström syndrome	
 Alström syndrome Vision (legal blindness, history of nystagmus in infancy/childhood, cone and rod dystrophy by ERG) History of dilated cardiomyopathy with congestive heart failure Hearing loss Hepatic dysfunction Renal failure Short stature 	3-14	Alström syndrome Vision (nystagmus, photophobia, decreased acuity, cone dystrophy [sometimes diagnosed as retinitis pigmentosa]² 	 History of dilated cardiomyopathy with congestive heart failure Hearing loss Advanced bone age Hepatic dysfunction
Male hypogonadism or female irregular menses and/or hyperandrogen	>15	Alström syndrome Vision (legal blindness, history of nystagmus in 	 History of dilated cardiomyopathy with congestive heart failure Hearing loss Hepatic dysfunction Renal failure

Albright Hereditary Osteodystrophy

- Inactivating mutation in GNAS Inherited from the mother, can be associated with resistance to certain hormones, in particular the PTH. This is Pseudohypoparathyroidism type 1A.
- When inherited from father , no hormone resistance but an AHO phenotype .



Albright Hereditary Osteodystrophy phenotype

- Developmental delay
- Short stature
- Round facies
- Short fourth and fifth metacarpals
- Brachydactyly
- Hypocalcemia (in PHP1
 A)



Fragile X Syndrome

- Obesity in upto 60% of cases
- 1/2,500 births X-linked
- FMR1 gene (Xq27.3)
- Intellectual disability, hyperkinetic behavior, macroorchidism, large ears, prominent jaw

FRAGILE X SYNDROME

Broad forehead Elongated face Large prominent ears Strabismus (crossed eyes) Highly arched palette

Hyperextensible JointsHypotoniHand callusesSoft, flesPectus ExcavatumEnlarged(indentation of chest)Flat feetMitral valve prolapseSeizures

Hypotonia (low muscle tone) Soft, fleshy skin Enlarged testicles Flat feet Seizures in 10%





Benefits of Identifying Genetic Cause

- Families relieved to know cause, feel less blame
- · Anticipatory guidance and screening
- Social support groups provide community
- · Management of hyperphagia as a physiologic medical condition
 - Distinct approach from traditional nutritional counseling for obesity
 - Food dosed and timed similar to prescription medications
 - In hypotonic conditions, 20% to 40% lower caloric needs due to decreased lean mass
 - Growth hormone therapy approved for PWS increases muscle mass and tone, reduces truncal obesity, potential cognitive benefits when initiated early
- Genetic diagnosis \rightarrow opportunity for targeted treatment

Styne DM, et al. J Clin Endocrinol Metab. 2017;102(3):709-57; Rubin DA, et al. Food Nutr Res. 2015;59:29427; Goldstone AP, et al. J Clin Endocrinol Metab. 2008;93(11):4183-97.

Precision Medicine Based on Genetics

- Leptin replacement for leptin deficiency
- Melanocortin agonist (setmelanotide) under investigation for LEPR, POMC, PCSK1, and CPE mutations
- Targeted approaches being studied for other rare and common variants of leptin pathway genes

Farooqi IS, et al. *J Endocrinol.* 2014;223(1):T63-70. Clement K, et al. *Nat Med.* 2018;24(5):551-5. Kühnen P, et al. *N Engl J Med.* 2016;375(3):240-6.

